Oncology
Why Micrel
As a company that specialises in developing advanced technology infusion devices, we are working with HCPs to meet the challenges of cancer care – designing and developing devices that increase the efficiency of infusion delivery and improve patient care.
Facts & Figures
More than 28 million people worldwide
have survived from cancers1
62% of patients
undergoing their first medical oncology visit (so not treated before)
already had weight loss2
Patients requiring
first-course chemotherapy p.a. will increase from 9.8 mil to 15 mil3
59% of patients currently
receiving anticancer treatment report pain4
A solution for every
oncology infusion
How Micrel can help
Rythmic™ Perf+
Ambulatory Infusion Pump
Micrel offers the Rythmic™ Perf+ that is designed to meet the safety, reliability and comfort that HCPs and oncology patients expect. The Rythmic™ Perf+ ensures that patients receive their full prescribed treatments, safely and in the right amount of time.
Mini Rythmic™ PN+
Ambulatory Infusion Pump
An increasing challenge in cancer care is ensuring that a cancer patient is receiving adequate nutrition, Mini Rythmic™ PN+ is ideal for administering parenteral nutrition when enteral nutrition is not an option.
Rythmic™ Evolution (Blue)
Ambulatory Infusion Pump
Micrel Rythmic™ Evolution provides tailored pain relief through a highly ambulatory and responsive device.
MICRELCARE
Infusion Remote Monitoring System
Each device has the optional support of MICRELCARE, the web-based care management platform that can help HCPs monitor their patients’ infusions remotely and provide further reassurance and information on the infusion status.
- References
- 1. 47 Interesting Facts About Cancer – The Fact File
- 2. Muscaritoli M et al., Oncotarget. 2017 Aug; 10 8(45): 79884-79896
- 3. The Lancet, Oncology, Brooke E Wolson et al. Vol 20, Issue 6, P769-780, June 01,2019
- 4. Van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-1449
Get in touch
Do you have a question?
